ARTICLE | Emerging Company Profile

Hangzhou Highlightll: Twice the target, hold the tox

TYK2/JAK1 inhibitor could treat a broad range of autoimmune diseases

By Jeff Cranmer, Executive Editor

July 3, 2021 2:04 AM GMT

Get Unlimited Access

Continue reading with a free trial.

Start a Free Trial Log In

Or Purchase This Article

BCIQ Company Profiles

Hangzhou Highlightll Pharmaceutical Co. Ltd.

BCIQ Target Profiles

Tyrosine kinase 2 (TYK2)

Janus kinase (JAK)

Janus kinase-1 (JAK-1)

Janus kinase-2 (JAK-2)

Janus kinase-3 (JAK-3)

Tumor necrosis factor (TNF)

BCIQ Company Profiles

Hangzhou Highlightll Pharmaceutical Co. Ltd.

BCIQ Target Profiles

Tyrosine kinase 2 (TYK2)

Janus kinase (JAK)

Janus kinase-1 (JAK-1)

Janus kinase-2 (JAK-2)

Janus kinase-3 (JAK-3)

Tumor necrosis factor (TNF)